Braveheart Bio raised $185 million to advance BHB-1893, a selective cardiac myosin inhibitor in late-stage clinical development for the treatment of obstructive hypertrophic cardiomyopathy, a rare genetic heart condition.
Braveheart Bio raised $185 million to advance BHB-1893, a selective cardiac myosin inhibitor in late-stage clinical development for the treatment of obstructive hypertrophic cardiomyopathy, a rare genetic heart condition.